GSK

Innovation & Solution Excellence Lead Oncology Business Unit Location: GSK Verona - Italy GSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significa

Innovation & Solution Excellence Lead Oncology Business Unit Location: GSK Verona - Italy GSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significa

Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol

Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol

Key Account Manager Hematology (Castilla y León - Asturias) Ubicación: Castilla y León Asturias. Residencia preferible en Asturias o Castilla y León( León / Valladolid) Fecha límite para aplicar: 10/02/2026Te gustaría impulsar el acceso a soluciones de alto valor en hematología y ma

Key Account Manager Hematology (Castilla y León - Asturias) Ubicación: Castilla y León Asturias. Residencia preferible en Asturias o Castilla y León( León / Valladolid) Fecha límite para aplicar: 10/02/2026Te gustaría impulsar el acceso a soluciones de alto valor en hematología y ma

Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol

Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol

We create a place where people can grow be their best be safe and feel welcome valued and included. We offer a competitive salary an annual bonus based on company performance healthcare and wellbeing programmes pension plan membership and shares and savings programme.We embrace modern

We create a place where people can grow be their best be safe and feel welcome valued and included. We offer a competitive salary an annual bonus based on company performance healthcare and wellbeing programmes pension plan membership and shares and savings programme.We embrace modern

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Position SummaryYou will represent the organization in national and international R&D collaborative fora strengthen our institutional footprint and shape funding and partnership opportunities across the scientific ecosystem. Working closely with national agencies international funders

Position SummaryYou will represent the organization in national and international R&D collaborative fora strengthen our institutional footprint and shape funding and partnership opportunities across the scientific ecosystem. Working closely with national agencies international funders

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol

Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol

Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol

Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol

Company OverviewAt GSK we have bold ambitions for patients aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines combining our understanding of the immune system with cutting-edge tec

Company OverviewAt GSK we have bold ambitions for patients aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines combining our understanding of the immune system with cutting-edge tec

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

This Manufacturing Specialist will provide support to the DP (Drug Product) Value Stream in Quality Systems GPS (Good Practice Standards) and improvement implementations authoring/coordinating/executing Quality Systems items (deviations change controls CAPAs (Corrective and Preventive

This Manufacturing Specialist will provide support to the DP (Drug Product) Value Stream in Quality Systems GPS (Good Practice Standards) and improvement implementations authoring/coordinating/executing Quality Systems items (deviations change controls CAPAs (Corrective and Preventive

Hello. Were Haleon. A new world-leading consumer health company. Shaped by all who join us. Together were improving everyday health for billions of people. By growing and innovating our global portfolio of category-leading brands including Sensodyne Panadol Advil Voltaren Theraflu Ot

Hello. Were Haleon. A new world-leading consumer health company. Shaped by all who join us. Together were improving everyday health for billions of people. By growing and innovating our global portfolio of category-leading brands including Sensodyne Panadol Advil Voltaren Theraflu Ot

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient

Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient